Last, but not least, galectin-3 (gal-3) is a novel biomarker that has not yet entered routine clinical practice but has been awarded increasing recognition for its involvement in the initiation and progression of various cardiac disorders, ranging from heart failure to hypertension and ischemic heart disease [71]. Here, LGALS3 is linked to hypertensive disorder.